EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Multizentrische StudieOpen Access

Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial

Tim Flaadt iD, Ruth L Ladenstein iD, Martin Ebinger iD, Holger N Lode iD, Helga Björk Arnardóttir, Ulrike Poetschger iD, Wolfgang Schwinger iD, Roland Meisel iD, Friedhelm R Schuster, Michaela Döring, Peter F Ambros iD, Manon Queudeville iD und 15 weitere

Journal of Clinical Oncology · 10.06.2023 · 41 (17) · 3135-3148

DOI: 10.1200/jco.22.01630 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.06.2023. Verfasst von Tim Flaadt und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, University Children's Hospital, Eberhard Karls University Tuebingen, Tuebingen, Germany. Hauptthemen laut MEDLINE: Neuroblastoma, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Patients with relapsed high-risk neuroblastoma (rHR-NB) have a poor prognosis. We hypothesized that graft-versus-neuroblastoma effects could be elicited by transplantation of haploidentical stem cells (haplo-SCT) exploiting cytotoxic functions of natural killer cells and their activation by the anti-GD2 antibody dinutuximab beta (DB). This phase I/II trial assessed safety, feasibility, and outcomes of immunotherapy with DB plus subcutaneous interleukin-2 (scIL2) after haplo-SCT in patients with rHR-NB. METHODS Patients age 1-21 years underwent T-/B-cell–depleted haplo-SCT followed by DB and scIL2. The primary end point ‘success of treatment’ encompassed patients receiving six cycles, being alive 180 days after end of trial treatment without progressive disease, unacceptable toxicity, acute graft-versus-host-disease (GvHD) ≥grade 3, or extensive chronic GvHD. RESULTS Seventy patients were screened, and 68 were eligible for immunotherapy. Median number of DB cycles was 6 (range, 1-9). Median number of scIL2 cycles was 3 (1−6). The primary end point was met by 37 patients (54.4%). Median observation time was 7.8 years. Five-year event-free survival (EFS) and overall survival from start of trial treatment were 43% (95% CI, 31 to 55) and 53% (95% CI, 41 to 65), respectively. Five-year EFS among patients in complete remission (CR; 52%; 95% CI, 31 to 69) or partial remission (44%; 95% CI, 27 to 60) before immunotherapy were significantly better compared with patients with nonresponse/mixed response/progressive disease (13%; 95% CI, 1 to 42; P = .026). Overall response rate in 43 patients with evidence of disease after haplo-SCT was 51% (22 patients), with 15 achieving CR (35%). Two patients developed GvHD grade 2 and 3 each. No unexpected adverse events occurred. CONCLUSION DB therapy after haplo-SCT in patients with rHR-NB is feasible, with low risk of inducing GvHD, and results in long-term remissions likely attributable to increased antineuroblastoma activity by donor-derived effector cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaHematopoietic Stem Cell TransplantationGraft vs Host DiseaseHumansInfantChild, PreschoolChildAdolescentYoung AdultAdultInterleukin-2Neoplasm Recurrence, LocalAntibodies, Monoclonal

Substanzen

Interleukin-2dinutuximabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Hematology and Oncology, University Children's Hospital, Eberhard Karls University Tuebingen, Tuebingen, Germany.
  • St Anna Children's Hospital and Children's Cancer Research Institute, Department of Studies and Statistics for Integrated Research and Projects, Medical University of Vienna, Vienna, Austria.
  • Department of Pediatrics, Medical University of Vienna, Vienna, Austria.
  • Department of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany.
  • Department for Studies and Statistics and Integrated Research, Children's Cancer Research Institute, Vienna, Austria.
  • Division of Pediatric Hematology-Oncology, Department of Pediatrics and Adolescent Medicine, Medical University Graz, Graz, Austria.

ORCID-Profile: Tim Flaadt, Ruth L Ladenstein, Martin Ebinger, Holger N Lode, Ulrike Poetschger, Wolfgang Schwinger, Roland Meisel, Peter F Ambros, Manon Queudeville, Jörg Fuchs, Jürgen Schäfer, Ursula Holzer, Tobias Feuchtinger, Thorsten Simon, Rupert Handgretinger, Peter Lang

Zitieren

APA

Flaadt, T., Ladenstein, R. L., Ebinger, M., Lode, H. N., Arnardóttir, H. B., Poetschger, U., Schwinger, W., Meisel, R., Schuster, F. R., Döring, M., Ambros, P. F., Queudeville, M., Fuchs, J., Warmann, S. W., Schäfer, J., Seitz, C., Schlegel, P., Brecht, I. B., Holzer, U., …, & Lang, P. (2023). Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial. Journal of Clinical Oncology, 41(17), 3135-3148. https://doi.org/10.1200/jco.22.01630

Vancouver

Flaadt T, Ladenstein RL, Ebinger M, Lode HN, Arnardóttir HB, Poetschger U, et al. Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial. Journal of Clinical Oncology. 2023;41(17):3135-3148. doi:10.1200/jco.22.01630

BibTeX
@article{Flaadt2023,
  author = {Flaadt, Tim and Ladenstein, Ruth L and Ebinger, Martin and Lode, Holger N and Arnardóttir, Helga Björk and Poetschger, Ulrike and Schwinger, Wolfgang and Meisel, Roland and Schuster, Friedhelm R and Döring, Michaela and Ambros, Peter F and Queudeville, Manon and Fuchs, Jörg and Warmann, Steven W and Schäfer, Jürgen and Seitz, Christian and Schlegel, Patrick and Brecht, Ines B and Holzer, Ursula and Feuchtinger, Tobias and Simon, Thorsten and Schulte, Johannes H and Eggert, Angelika and Teltschik, Heiko-Manuel and Illhardt, Toni and Handgretinger, Rupert and Lang, Peter},
  title = {Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {17},
  pages = {3135--3148},
  doi = {10.1200/jco.22.01630}
}
Kostenlos starten →